Drug doses can be tailored to provide safe and effective therapy for individual patients (DNA-Guided Medicine).
Health Personalized (Overview)
It seems that nearly everything is being customized today. When we choose a product, we can order just the right size or color or set of options.
Medicine is just now catching up. The “one-size-fits-all” approach to prescribing medications is giving way to an advanced, modern method of drug selection based on the capacity of the individual to process (metabolize) the prescription.
And about 25 percent of people have an above-average ability to metabolize drugs. This capacity could lead to lack of efficacy, as the medication is broken down before it has its effect.
You may have tried different dosages of medications or some of your prescriptions may have been switched in an effort to find the best result.
The HILOmet PhyzioType™System tests identify whether you are a high, average, or low metabolic function individual for medicines. Informed with your fundamental metabolic benchmark, your clinician can personalize medication prescription, and render the trial-and-error approach to drug treatment truly a thing of the past.
Available Testing is covered by most insurance companies. Contact us for more information.
The Genomas* mission is to be the leading company in DNA-guided medicine enabling a new standard of personalized medicine based on the patient’s genome and innate constitution. Our PhyzioType products give physicians the ability to personalize clinical management by comparing a patient’s response from drugs in a therapeutic class and selecting the drug with the greatest efficacy and least risk of side effects. Each of our PhyzioType Systems is non-invasive and designed to deliver the following key benefits:
- Clinically Actionable Information. Personalized information regarding an individual’s drug response for major drugs in a therapeutic class to provide treatment guidance to physicians
- Objective Results. Statistically predictive analysis which will allow the physician to objectively recommend an initial treatment course
- Noninvasive Tests. Performance using a sample of the patient’s peripheral blood or a buccal swab.
- Quality Control. All tests processed at our own Laboratory of Personalized Health to provide consistent quality and ensure timely turnaround
- Rapid Turnaround. Binary nature of the gene SNPs lends itself to “digital” data analysis with turnaround speed and analytical simplification substantially enhanced compared to other platforms in the industry reliant on “analogue” expression of genes and proteins.
Laboratory of Personalized Health (LPH): Delivering Personalized Medicine in Real-time
The effectiveness of drugs and their potential for both benefit and side effects are not only the result of drug selection and dose but also the rate of drug metabolism and target interaction. For many drugs, this metabolism is accomplished by the Cytochrome P450 (CYP450) enzyme system located in the liver.
Variability in the CYP450 system, accumulated in humans since prehistoric times, results in strikingly different drug levels, drug effectiveness and drug safety among individuals when the recommended dose is designed to treat the “average” person. These variances, particularly relevant to drugs used in mental health, cardio-metabolic disease, and pain control, can now be measured by DNA typing before treatment. Drug doses can then be tailored to provide safe and effective therapy for individual patients (DNA-Guided Medicine).
The Laboratory for Personalized Health analyzes the CYP2C9, CYP2C19, and CYP2D6 genes simply from a blood sample or buccal swab from the patient. LPH then assists in the interpretation of these results for DNA-guided medical management of serious side effects and individualized optimization of therapy. The genotype results and guidance delivered by LPH markedly improve the safetly and efficacy of drug therapy by providing:
- Assessment of the patient’s innate functional status for the 3 key CYP450 isoenzymes relevant to the metabolism of neuro-psychiatric and cardio-metabolic drugs: CYP2D6, CYP2C9, and CYP2C19.
- High-resolution genotyping of a total of 37 variants in the genes coding for these isoenzymes: CYP2D6 (20 alleles),CYP2C9 (7 alleles), CYP2C19 (10 alleles).
- Well-characterized ultra-rapid promoter alleles for genes CYP2D6 and CYP2C19 (*2a and *17, respectively) conferring gain of metabolic function in carriers
- Objective Indices for Metabolic Reserve and Alteration, Allele and Gene Alteration
- Analysis of the VKOR gene coding for Vitamin K Epoxide Reductase, the target for the anticoagulant drug warfarin, and interpretation for gene-guided warfarin dosin
*Genomas is a biomedical company delivering Personalized Medicine to modern clinical practice. The company develops revolutionary PhyzioType Systems for DNA-guided management and prescription of drugs used to treat mental illness, pain, heart disease, and diabetes. PhyzioType Systems are designed to provide physicians with an unprecedented capability to select for each patient the safest and most effective drug to achieve treatment goals and enhance patient compliance. PhyzioType Systems are composed of an ensemble of inherited DNA polymorphisms genotyped by arrays and interpreted by a bioclinical algorithm in order to convey to physicians predicted comparisons of side effect risk and efficacy among drugs for the individual patient.